Published in Mental Health Business Week, July 23rd, 2005
According to recent research published in the journal Cancer, "Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor that induces an early and dramatic response in 10% of patients with advanced NSCLC. Long-term outcome and patterns of disease recurrence after response have not been described."
"The authors evaluated 139 patients with NSCLC treated with gefitinib at Memorial Sloan-Kettering Cancer Center between 1998 and 2002. They focused on patterns of disease...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.